BioCryst Pharmaceuticals (BCRX) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 28.6% versus a gain of 20.9%. Over five years, BCRX leads with a -44.5% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($2.98 billion vs $2.12 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | DNLI |
|---|---|---|
| Share price | $8.29 | $18.67 |
| Market cap | $2.12B | $2.98B |
| 1-day change | -1.31% | -2.57% |
| YTD return | +7.69% | +16.05% |
| 1-year return | +20.86% | +28.59% |
| 5-year return | -44.48% | -57.95% |
| Forward P/E | 8.82 | — |
| EPS (TTM) | $-1.40 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-512.54M |
| 52-week high | $11.22 | $27.30 |
| 52-week low | $6.00 | $13.75 |
| Distance from 52-week high | -26.11% | -31.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +150.06% | +93.16% |
| Average volume | 4.11M | 1.61M |
| Shares outstanding | 255.54M | 159.85M |
| Employees | 435 | 503 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
BCRX vs DNLI FAQ
Which is bigger, BioCryst Pharmaceuticals or Denali Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.98B compared with $2.12B for BioCryst Pharmaceuticals (BCRX).
Which stock has performed better over the past year, BCRX or DNLI?
DNLI returned +28.59% over the past 12 months, compared with +20.86% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.